

### United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/663,481	09/15/2000	Mark D. Fidock	PC10350AGPR	2752	
75	90 02/05/2003				
Gregg C Benson			EXAMINER		
Pfizer Inc			SAIDHA, TEKCHAND		
Patent Department MS 4159 Eastern Point Road					
Groton, CT 06			ART UNIT	PAPER NUMBER	
			1652	7	
		DATE MAILED: 02/05/2003			

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No. Applicant(s) Fidock, Mark D

Examiner T. Saidha Group Art Unit

7

-The MAILING DATE of this communication appears on the cover sheet beneath the correspondence address-**Period for Reply** A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE \_\_\_\_\_MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, such period shall, by default, expire SIX (6) MONTHS from the mailing date of this communication . - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). **Status** 9/15/00/Prelimingry Invendmen Responsive to communication(s) filed on ☐ This action is FINAL. ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 1 1; 453 O.G. 213. is/are pending in the application. is/are withdrawn from consideration. □ Claim(s)\_ is/are allowed. is/are rejected. □ Claim(s) is/are objected to. X Claim(s). are subject to restriction or election requirement. **Application Papers** ☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948. ☐ The proposed drawing correction, filed on\_\_\_\_\_ \_\_\_\_\_ is approved disapproved. ☐ The drawing(s) filed on\_\_\_\_\_ \_\_\_\_\_ is/are objected to by the Examiner. ☐ The specification is objected to by the Examiner. ☐ The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 (a)-(d) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 11 9(a)-(d). □ All □ Some\* □ None of the CERTIFIED copies of the priority documents have been ☐ received in Application No. (Series Code/Serial Number)\_ ☐ received in this national stage application from the International Bureau (PCT Rule 1 7.2(a)). \*Certified copies not received:\_ Attachment(s) ☐ Information Disclosure Statement(s), PTO-1449, Paper No(s). \_\_\_\_\_ ☐ Interview Summary, PTO-413 ☐ Notice of Reference(s) Cited, PTO-892 ☐ Notice of Informal Patent Application, PTO-152 ☐ Notice of Draftsperson's Patent Drawing Review, PTO-948 □ Other\_ Office Action Summary

Application/Control Number: 09/663481

Art Unit: 1652

#### Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1, 13, 15 & 21, drawn to a recombinant phosphodiesterase PDE1B2 of SEQ
     ID NO: 1, classified in class 435, subclass 196.
  - II. Claims 2-4, 6-7, 14 & 22, drawn to nucleic acid encoding PDE, vector & host cell, classified in class 435, subclass 252.3
  - III. Claims 8-10 & 19-20, drawn to an assay method of identifying a compound effecting PDE activity, classified in class 435, subclass 69.2.
  - IV. Claims 11-12 & 16, drawn to a method effecting the in *vivo* PDE activity, classified on class 435, subclass 19.
  - V. Claims 24-27, drawn to assay method for identifying an agent that can effect
     PDE expression, classified in class 435, subclass 6.
- 2. The inventions are distinct, each from the other because of the following reasons:

The DNA of group II is related to the protein of group I by virtue of the fact that the DNA codes for the protein. The DNA molecule has utility for the recombinant production of the protein in a host cell. Although the DNA and the protein are related, since the DNA encodes the specifically claimed protein, they are distinct inventions because the protein product can be made by other and materially distinct processes, such as purification from the natural source. Further, DNA can be used for processes other than the production of protein, such as nucleic acid hybridization assays.

Application/Control Number: 09/822635 Page 3

Art Unit: 1652

3. Inventions I and III-V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product i.e., PDE enzyme, as claimed in Group I can be used in a materially different process such as in making antibodies, rather than in methods for affecting in vivo PDE activity (Groups IV) or for identifying inhibitor/activator compounds of PDE enzyme or PDE expression (Group V).

- 4. The product of Invention II are not used in the methods of Invention III-V. Therefore, Inventions III-V are patentably distinct from Invention II.
- 5. The methods of Inventions III, IV and V require different products and steps and have different endpoints. Therefore, Inventions III, IV and V are patentably distinct.
- 6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventor ship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventor ship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

## 7. Sequence Rules

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s)



Art Unit: 1652

set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. See the enclosed notice to comply. Specifically, Rule 1.822(e) requires the use of three letter abbreviation for amino acids.

#### New Sequence Rules

Since the effective filing date after July 1, 1998, Applicants should follow the New Rule Format and submit a new Sequence Listing (both in electronic and paper format). Compliance according to the requirements of 37 CFR 1.821 through 1.825 is required.

- 8. The amendment to the claims filed on 9.15.00 (Paper No. 4) does not comply with the requirements of 37 CFR 1.121(c) because the amendment to the claims has not been entered because it requests the addition of more **than 5 words** in any one claim. See 37 CFR 1.121(c) below: Amendments to the claims 11, 12 & 16, filed after March 1, 2001 must comply with 37 CFR 1.121(c) which states:
  - (c) Claims.
  - (1) <u>Amendment by rewriting, directions to cancel or add</u>: Amendments to a claim must be made by rewriting such claim with all changes (e.g., additions, deletions, modifications) included. The rewriting of a claim (with the same number) will be construed as directing the cancellation of the previous version of that claim. A claim may also be canceled by an instruction.
  - (I) A rewritten or newly added claim must be in clean form, that is, without markings to indicate the changes that have been made. A parenthetical expression should follow the claim number indicating the status of the claim as amended or newly added (e.g., "amended," "twice amended," or "new").
  - (ii) If a claim is amended by rewriting such claim with the same number, the amendment must be accompanied by another version of the rewritten claim, on one or more pages separate from the amendment, marked up to show all the changes relative to the previous version of that claim. A parenthetical expression should follow the claim number indicating the status of the claim, e.g., "amended," "twice amended," etc. The parenthetical expression

Art Unit: 1652

"amended," "twice amended," etc. should be the same for both the clean version of the claim under paragraph (c)(1)(i) of this section and the marked up version under this paragraph. The changes may be shown by brackets (for deleted matter) or underlining (for added matter), or by any equivalent marking system. A marked up version does not have to be supplied for an added claim or a canceled claim as it is sufficient to state that a particular claim has been added, or canceled.

(2) A claim canceled by amendment (deleted in its entirety) may be reinstated only by a subsequent amendment presenting the claim as a new claim with a new claim number.

Since the reply filed on appears to be bona fide, applicant is given a TIME PERIOD of **ONE** 

(1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to submit an amendment in compliance with 37 CFR 1.121 in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tekchand Saidha (Ph.D.) whose telephone number is (703) 305-6595. The examiner can normally be reached on Monday-Friday from 8:15 am to 4:45 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy, can be reached at (703) 308-3804. The fax phone number for this Group is (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Tekchand Saidha

Primary Examiner, Art Unit 1652

February 3, 2003



UNITED STATE PARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT		А	TTORNEY DOCKET NO.	
				<del></del>		
				<del></del>		
				•	EXAMINER	
					ART UNIT	PAPER NUMBER
					DATE MAILED:	

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Any inquiry concerning this communication should be directed to Examiner Tekchand Saidha, Art Unit 1652, whose telephone number is (703)305-6595.

An inquiry of a general nature or relating to the status of the application should be directed to the group receptionist whose telephone number is (703)308-0196.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for reply beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures with the response.

TEKCHAND SAIDHA

Application No. NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CON NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s): This application clearly falls to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990. 2. This application does not contain, as a separate part of the disclosure on paper copy, a \*Sequence Listing" as required by 37 C.F.R. 1.821(c). 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as Indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). 7. Other: Applicant should follow the format of the attached sample statement to request that the CRF filed In the parent application be used to create a CRF in this application. **Applicant Must Provide:** An Initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An Initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE